

| Accepted Abstracts from the Swedish MS Registry (SMSReg) |                                                                                                                                            |                                 |                                                              |
|----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|--------------------------------------------------------------|
| Presenting Author                                        | Title                                                                                                                                      | Presentation Type (Oral/Poster) | Session, Date (GMT-4)                                        |
| Peter Alping                                             | Risk of Inflammatory Bowel Disease Following Anti-CD20 Treatment in Multiple Sclerosis: A Population-Based Cohort Study                    | Oral (O100)                     | Free Communications Session 5, 22 Oct 2026, 9:50 AM-10:00 AM |
| Timothy Copeland                                         | Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis: A Swedish Registry-Based Cohort Study             | Oral (O051)                     | Scientific Session 14, 23 Oct 2026, 9:19 AM - 9:26 AM        |
| Elena Flavia Mouresan                                    | Post authorization drug safety monitoring using multiple sclerosis patient registries                                                      | Poster (P0413)                  | Poster Session 1, 21 Oct 2026                                |
| Elena Flavia Mouresan                                    | Extension of the RIFUND-MS Target Trial Emulation to a Broader Real-World Population in the Swedish MS registry.                           | Poster (P0414)                  | Poster Session 1, 21 Oct 2026                                |
| Lars Forsberg                                            | Towards Prediction of Progression Independent of Relapses In Multiple Sclerosis by Integrating Clinical Data and Patient-Reported Outcomes | Poster (P1105)                  | Poster Session 2, 22 Oct 2026                                |
| Lars Forsberg                                            | Exploring Large Language Models for Clinical Interpretation in Multiple Sclerosis                                                          | Poster (P1106)                  | Poster Session 2, 22 Oct 2026                                |
| Peter Alping                                             | Severity of the Multiple Sclerosis Prodrome is Associated with Later Disability                                                            | Poster (P1113)                  | Poster Session 2, 22 Oct 2026                                |
| Astrid Pedersen                                          | Evolving age at onset and diagnosis of progressive and relapsing MS in Sweden 2001-2021                                                    | ePoster (EP0039)                | ePoster                                                      |

| Accepted Abstracts from the German MS Registry (GMSR) |                                                                                                                                                       |                                 |                               |
|-------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-------------------------------|
| Presenting Author                                     | Title                                                                                                                                                 | Presentation Type (Oral/Poster) | Session, Date (GMT-4)         |
| David Ellenberger                                     | Cladribine tablets in MS: Long-term management 4+ years post-initiation across age groups.                                                            | Poster (P0408)                  | Poster Session 1, 21 Oct 2026 |
| David Ellenberger                                     | Prevalence and treatment of symptomatic sexual dysfunction in people with multiple sclerosis: 10-year real-world evidence from the German MS Register | Poster (P1059)                  | Poster Session 2, 22 Oct 2026 |
| David Ellenberger                                     | Improving long-term disability outcomes in multiple sclerosis over 30 years: A registry-based cohort analysis                                         | Poster (P1093)                  | Poster Session 2, 22 Oct 2026 |
| Simon Faissner                                        | Influence of Anovulation and Menopause on the Course of Multiple Sclerosis – the prospective LOTUS-MS Study                                           | Poster (P1142)                  | Poster Session 2, 22 Oct 2026 |

| Accepted Abstracts from the Czech MS Registry (ReMuS) |                                                                                                                                                                                               |                                 |                               |
|-------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-------------------------------|
| Presenting Author                                     | Title                                                                                                                                                                                         | Presentation Type (Oral/Poster) | Session, Date (GMT-4)         |
| Gregor Fistravec                                      | Personalized MS risk prediction for everyone: implementing the DAAE score in a Common Data Model                                                                                              | Poster (P0081)                  | Poster Session 1, 21 Oct 2026 |
| Marco Battaglini                                      | Cladribine Tablets Treatment after 4 years: Impact on MRI lesion accumulation                                                                                                                 | Poster (P0256)                  | Poster Session 1, 21 Oct 2026 |
| Tomas Uher                                            | Data-Driven MRI Phenotypes in Multiple Sclerosis                                                                                                                                              | Poster (P0307)                  | Poster Session 1, 21 Oct 2026 |
| Dominika Stastna                                      | Up to 3-Year Ponesimod Effectiveness and Treatment Patterns in 964 Patients With MS: A Czech National ReMuS Registry Analysis in the Multi-S1P Modulator Era                                  | Poster (P0410)                  | Poster Session 1, 21 Oct 2026 |
| Gregor Fistravec                                      | Real-World Treatment Patterns with Cladribine Tablets Beyond Year 5: Additional Treatment, Treatment Switching, and Treatment-Free Status in the CLADRISE Study from the Czech ReMuS Registry | Poster (P0418)                  | Poster Session 1, 21 Oct 2026 |
| Tomas Uher                                            | MRI outperforms clinical predictors of disease activity after cladribine initiation in multiple sclerosis                                                                                     | Poster (P0456)                  | Poster Session 1, 21 Oct 2026 |
| Dominika Stastna                                      | Infections and Malignancies in Multiple Sclerosis: Meta-Analysis and Real-World Data From the Czech National ReMuS Registry                                                                   | Poster (P1151)                  | Poster Session 1, 21 Oct 2026 |
| Tomas Uher                                            | EBNA-1 IgG Defines an MS-Specific Immunological Signature Linking EBV Immunity to Intrathecal B-Cell Activity                                                                                 | Poster (P1385)                  | Poster Session 2, 22 Oct 2026 |
| Dominika Stastna                                      | Multiple Sclerosis Without a Typical Attack? Multimodal Phenotyping of RIS and Subclinical MS Under the 2024 McDonald Criteria                                                                | ePoster (P2020)                 | ePoster                       |
| Dana Horakova                                         | Vigilance Is Key: Progressive Multifocal Leukoencephalopathy in the Czech MS Population, 2002–2026                                                                                            | ePoster (P2612)                 | ePoster                       |
| Natalia Komornikova                                   | Clinico-Radiological Agreement Reveals Subtypes of Temporal Progression in MS: A Longitudinal Single-Center Study                                                                             | ePoster (P2687)                 | ePoster                       |

| Accepted Abstracts from the French MS Registry (OFSEP) |                                                                                                                                                                                                             |                                 |                                                         |
|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|---------------------------------------------------------|
| Presenting Author                                      | Title                                                                                                                                                                                                       | Presentation Type (Oral/Poster) | Session, Date (GMT-4)                                   |
| Mathilde Liffra                                        | Brain- versus Spinal Cord–Predominant Phenotypes in Multiple Sclerosis: Demographic Characteristics and Associations with Disability Progression in a Large Cohort with Brain and Whole Spinal Cord Imaging | Oral (O006)                     | Scientific Session 2, 21 Oct 2026, 11:57 AM - 12:04 PM  |
| Chao Zhu                                               | Comparative Effectiveness of Ofatumumab vs Ocrelizumab in Relapsing Multiple Sclerosis : A Target Trial Emulation Using MSBase and OFSEP                                                                    | Oral (O092)                     | Scientific Session 3, 21 Oct 2026, 03:20 PM - 03:30 PM  |
| Manon Rival                                            | Serum GFAP and age accurately distinguish AQP4-IgG positive and double seronegative NMOSD from MOGAD after a recent attack                                                                                  | Oral (O036)                     | Scientific Session 10, 22 Oct 2026, 03:41 PM - 03:48 PM |
| Edouard Januel                                         | Air pollution and the risk of multiple sclerosis relapse risk in the Paris region: insights from the CONFISEP study                                                                                         | Poster (P0151)                  | Poster Session 1, 21 Oct 2026                           |
| Anne Kerbrat                                           | Measurement of Quantitative Susceptibility Mapping of the spinal cord in people with Multiple Sclerosis and Association With Clinical Disability                                                            | Poster (P0207)                  | Poster Session 1, 21 Oct 2026                           |
| Louis Padé                                             | Automated Detection of New Spinal Cord Lesions Between Two Longitudinal MRI Scans in people with MS could Improve Radiologists Sensitivity                                                                  | Poster (P0250)                  | Poster Session 1, 21 Oct 2026                           |
| Antoine Gavaille                                       | Comparative Effectiveness of Initial Therapies in Treatment-Naïve Relapsing-Remitting Multiple Sclerosis: a Multi-Arm Target Trial Emulation with Causal Mediation Analysis For Relapse Contribution        | Poster (P0394)                  | Poster Session 1, 21 Oct 2026                           |
| Nicolas Collongues                                     | Escalation vs Induction Therapeutic Strategy in Patients With Late Onset Multiple Sclerosis                                                                                                                 | Poster (P1451)                  | Poster Session 2, 22 Oct 2026                           |
| Christine Lebrun-Frenay                                | From Incidental MRI Findings to Multiple Sclerosis: Do the 2024 McDonald Criteria Outperform the 2023 RIS Definition?                                                                                       | Poster (P1494)                  | Poster Session 2, 22 Oct 2026                           |
| Pierre Clavelou                                        | Ovarian Reserve in Women with Multiple Sclerosis: A Cross-Sectional Study                                                                                                                                   | ePoster (EP2251)                | ePoster                                                 |
| Françoise Durand-Dubief                                | Should annual brain MRI monitoring be performed in all treated people with MS? Real-World detection rates of subclinical disease activity by treatment, duration, and age                                   | ePoster (EP2375)                | ePoster                                                 |
| Jonathan Ciron                                         | Real-World Persistence With Ofatumumab in Patients With Relapsing Form of MS in France: Interim Results From the ASTREOS Study Based on OFSEP Data (EDMUS Database)                                         | ePoster (EP2651)                | ePoster                                                 |

| Accepted Abstracts from the Danish MS Registry (DMSR) |                                                                                                                                                                      |                                 |                                                               |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|---------------------------------------------------------------|
| Presenting Author                                     | Title                                                                                                                                                                | Presentation Type (Oral/Poster) | Session, Date (GMT-4)                                         |
| Melinda Magyari                                       | Disease-Transition Network Modeling of the Multiple Sclerosis Prodrome: A Danish Nationwide Study                                                                    | Oral (O082)                     | Free Communications Session 1, 21 Oct 2026, 12:10 PM-12:20 PM |
| Eliza Viktoria Varju                                  | Effectiveness of Escalation vs. Early High-Efficacy Therapies on Progression Independent of Relapse Activity in Multiple Sclerosis: A Danish nationwide study        | Oral (O093)                     | Free Communications Session 3, 21 Oct 2026, 3:30 PM-3:40 PM   |
| Elisabeth Framke                                      | Familial risk of multiple sclerosis: A nationwide registry-based study in Denmark                                                                                    | Poster (P0044)                  | Poster Session 1, 21 Oct 2026                                 |
| Luigi Pontieri                                        | Ofatumumab Versus Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nation-Wide Cohort Study                                                                  | Poster (P0433)                  | Poster Session 1, 21 Oct 2026                                 |
| Melinda Magyari                                       | Age- and Sex-Specific Effects of Initial High-Efficacy Therapy Versus an Escalation Strategy in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis | Poster (P0441)                  | Poster Session 1, 21 Oct 2026                                 |
| Salvatore Iacono                                      | Comparison of Semaglutide and Sodium-Glucose Cotransporter 2 inhibitors on disability accrual in patients with Multiple Sclerosis: a study on the Danish MS Register | Poster (P0449)                  | Poster Session 1, 21 Oct 2026                                 |
| Agata Beczek                                          | Preconception Use of Disease Modifying Therapy in Women with MS: A 25-Year Danish Nationwide Study                                                                   | Poster (P1125)                  | Poster Session 2, 22 Oct 2026                                 |

| Accepted Abstracts from MS Base |                                                                                                                                         |                                 |                                                               |
|---------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|---------------------------------------------------------------|
| Presenting Author               | Title                                                                                                                                   | Presentation Type (Oral/Poster) | Session, Date (GMT-4)                                         |
| Cristina Torres-Mora            | Subclinical MRI activity independently predicts the development of SPMS, PIRA and confirmed disability worsening in multiple sclerosis  | Oral (O083)                     | Free Communications Session 2, 21 Oct 2026, 11:20 AM-11:30 AM |
| Chao Zhu                        | Comparative Effectiveness of Ofatumumab vs Ocrelizumab in Relapsing Multiple Sclerosis: A Target Trial Emulation Using MSBase and OFSEP | Oral (O092)                     | Free Communications Session 3, 21 Oct 2026, 3:20 PM-3:30 PM   |
| Winston Dzau                    | Emulation of a placebo-controlled natalizumab trial in multiple sclerosis: insights from AFFIRM and MSBase registry                     | Oral (O094)                     | Free Communications Session 3, 21 Oct 2026, 3:40 PM-3:50 PM   |
| Daniela Soares Régua            | Validation of the 2025ECTRIMS Consensus Recommendations on DMT Discontinuation: A Target Trial Emulation Using MSBase                   | Oral (O0017)                    | Scientific Session 6, 22 Oct 2026, 11:50 AM - 11:57 AM        |
| Yi Chao Foong                   | Older Age Predicts Relapse-Associated Worsening in Multiple Sclerosis                                                                   | Oral (O0018)                    | Scientific Session 6, 22 Oct 2026, 11:57 AM - 12:04 PM        |
| Jannis Müller                   | Exit Strategies after Anti-Cell Trafficking Therapies in Multiple Sclerosis Patients aged ≥50 years: a Target Trial Emulation           | Oral (O0020)                    | Scientific Session 6, 22 Oct 2026, 12:11 PM - 12:18 PM        |
| Vilija Jokubaitis               | Pregnancy-Associated Inflammatory Lesion Activity and Brain Volume Changes in Contemporary Women with Multiple Sclerosis                | Oral (O0049)                    | Scientific Session 14, 23 Oct 2026, 9:05 AM - 9:12 AM         |
| Emanuele D'Amico                | Temporal Trends in Live Birth Rates and Treatment Discontinuation in Women with Multiple Sclerosis: A 30-Year MSBase Study              | Oral (O0052)                    | Scientific Session 14, 23 Oct 2026, 9:26 AM - 9:33 AM         |
| Kayla Ward                      | Impact of Multiple Sclerosis Disease-modifying Therapies on Chronic Lesion Tissue Expansion                                             | Poster (P0243)                  | Poster Session 1, 21 Oct 2026                                 |
| Michael Hayes                   | Chronic Lesion Expansion as a Predictor of Disability Progression in Relapsing Multiple Sclerosis                                       | Poster (P0264)                  | Poster Session 1, 21 Oct 2026                                 |
| Hassam Iqbal                    | Individualized treatment response in multiple sclerosis predicted with machine learning                                                 | Poster (P0374)                  | Poster Session 1, 21 Oct 2026                                 |
| Samuel Klistorner               | Effect of Cladribine on Chronic Lesion Tissue Expansion in Relapsing–Remitting Multiple Sclerosis                                       | Poster (P0389)                  | Poster Session 1, 21 Oct 2026                                 |
| Dagmawi Haile                   | A Causal Effect of Early High-Efficacy Therapy Across Ages                                                                              | Poster (P0407)                  | Poster Session 1, 21 Oct 2026                                 |
| Helmut Butzkueven               | Real-World Effectiveness and Safety of First-Line Ocrelizumab Treatment in Early-Stage Relapsing Multiple Sclerosis                     | Poster (P0420)                  | Poster Session 1, 21 Oct 2026                                 |
| Izanne Roos                     | High-efficacy Therapy Controls Relapses More Effectively Than Progression Independent of Relapse Activity                               | Poster (P1099)                  | Poster Session 2, 22 Oct 2026                                 |
| Xanat Jazmín López Camaño       | Progression Independent Of Relapse Activity Is A Late Clinical Marker Of Disability Accumulation In Relapsing Multiple Sclerosis        | Poster (P1123)                  | Poster Session 2, 22 Oct 2026                                 |

|                        |                                                                                                                                                                                             |                  |                                                             |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-------------------------------------------------------------|
| Vilija Jokubaitis      | Structural Brain Changes Across Pregnancy and the Postpartum Period in Women with Multiple Sclerosis                                                                                        | Poster (P1143)   | Poster Session 2, 22 Oct 2026                               |
| Nathaniel Lizak        | Comparison Of Siponimod And High-Efficacy Disease-Modifying Therapies In Secondary Progressive MS                                                                                           | Poster (P1449)   | Poster Session 2, 22 Oct 2026                               |
| Sifat Sharmin          | Optimal Responders to Autologous Hematopoietic Stem Cell Transplant Versus Natalizumab in Relapsing-remitting Multiple Sclerosis                                                            | Poster (P1460)   | Poster Session 2, 22 Oct 2026                               |
| Karla Valdós Rodríguez | Early Disease-Modifying Therapy Is Associated with Confirmed Disability Improvement After NMOSD Attacks                                                                                     | ePoster (EP2190) | ePoster                                                     |
| Helmut Butzkueven      | Real-World Comparative Effectiveness and Persistence of Cladribine Tablets vs Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Updates from the MSBase Registry | ePoster (EP2640) | ePoster                                                     |
| Helmut Butzkueven      | Real-world Experience with Cladribine Tablets in the MSBase Registry 2026 Update                                                                                                            | ePoster (EP2642) | ePoster                                                     |
| Anneke van der Walt    | Real World Effectiveness of Ofatumumab in Australian Adults with Relapsing MS: A Retrospective Analysis of the MSBase Registry                                                              | ePoster (EP2708) | ePoster                                                     |
| Tim Spelman            | Real-world relapses and disability outcomes in non-highly active relapsing multiple sclerosis patients treated with ofatumumab: an MSBase registry analysis                                 | ePoster (EP2710) | ePoster                                                     |
| Anneke van der Walt    | Real-World Outcomes of Ofatumumab in Relapsing MS: EAFToS Part II, a Novel Study Linking MSGo with Other Real-World Clinical Data Sources                                                   | ePoster (EP2726) | ePoster                                                     |
| Chao Zhu               | Comparative Effectiveness of Ofatumumab vs Ocrelizumab in Relapsing Multiple Sclerosis: A Target Trial Emulation Using MSBase and OFSEP                                                     | Oral (O092)      | Free Communications Session 3, 21 Oct 2026, 3:20 PM-3:30 PM |
| Winston Dzau           | Emulation of a placebo-controlled natalizumab trial in multiple sclerosis: insights from AFFIRM and MSBase registry                                                                         | Oral (O094)      | Free Communications Session 3, 21 Oct 2026, 3:40 PM-3:50 PM |
| Daniela Soares Régua   | Validation of the 2025ECTRIMS Consensus Recommendations on DMT Discontinuation: A Target Trial Emulation Using MSBase                                                                       | Oral (O0017)     | Scientific Session 6, 22 Oct 2026, 11:50 AM - 11:57 AM      |
| Yi Chao Foong          | Older Age Predicts Relapse-Associated Worsening in Multiple Sclerosis                                                                                                                       | Oral (O0018)     | Scientific Session 6, 22 Oct 2026, 11:57 AM - 12:04 PM      |
| Jannis Müller          | Exit Strategies after Anti-Cell Trafficking Therapies in Multiple Sclerosis Patients aged ≥50 years: a Target Trial Emulation                                                               | Oral (O0020)     | Scientific Session 6, 22 Oct 2026, 12:11 PM - 12:18 PM      |
| Vilija Jokubaitis      | Pregnancy-Associated Inflammatory Lesion Activity and Brain Volume Changes in Contemporary Women with Multiple Sclerosis                                                                    | Oral (O0049)     | Scientific Session 14, 23 Oct 2026, 9:05 AM - 9:12 AM       |
| Emanuele D'Amico       | Temporal Trends in Live Birth Rates and Treatment Discontinuation in Women with Multiple Sclerosis: A 30-Year MSBase Study                                                                  | Oral (O0052)     | Scientific Session 14, 23 Oct 2026, 9:26 AM - 9:33 AM       |

|               |                                                                                                   |                |                               |
|---------------|---------------------------------------------------------------------------------------------------|----------------|-------------------------------|
| Kayla Ward    | Impact of Multiple Sclerosis Disease-modifying Therapies on Chronic Lesion Tissue Expansion       | Poster (P0243) | Poster Session 1, 21 Oct 2026 |
| Michael Hayes | Chronic Lesion Expansion as a Predictor of Disability Progression in Relapsing Multiple Sclerosis | Poster (P0264) | Poster Session 1, 21 Oct 2026 |
| Hassam Iqbal  | Individualized treatment response in multiple sclerosis predicted with machine learning           | Poster (P0374) | Poster Session 1, 21 Oct 2026 |

### Accepted Abstracts from the Italian MS Registry (RISM)

| Presenting Author   | Title                                                                                                                                                                                                                                          | Presentation Type (Oral/Poster) | Session, Date (GMT-4)                                         |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|---------------------------------------------------------------|
| Damiano Paolicelli  | Profiling the long-term risk of Severe Adverse Events in a cohort of Multiple Sclerosis patients treated with different treatment sequences:Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study) | Oral (O104)                     | Free Communications Session 5, 22 Oct 2026, 10:30 AM-10:40 AM |
| Pasquale Paletta    | Accelerating Diagnosis and Treatment in Pediatric Onset Multiple Sclerosis: 25 Years of Real-World Evidence from the Italian Multiple Sclerosis and Related Disorders Register                                                                 | Poster (P0036)                  | Poster Session 1, 21 Oct 2026                                 |
| Davide Quartana     | Incidence and Risk Factors for Pneumonia in a Prospective, Real-World, Multicentric Cohort of Multiple Sclerosis Patients Treated With Anti-CD20 Monoclonal Antibodies                                                                         | Poster (P0454)                  | Poster Session 1, 21 Oct 2026                                 |
| Alessandro Cruciani | Education Expands the Window of Preserved Function in Multiple Sclerosis                                                                                                                                                                       | Poster (P1091)                  | Poster Session 2, 22 Oct 2026                                 |
| Pietro Iaffaldano   | Earlier diagnosis is associated with improved disability outcomes in Primary Progressive Multiple Sclerosis: impact of McDonald criteria revisions in a large real-world cohort                                                                | ePoster (EP2230)                | ePoster                                                       |
| Marco Salivetto     | European Mapping of Multiple Sclerosis Registries for the Evaluation of Safety Outcomes: A Scoping Review                                                                                                                                      | ePoster (EP2747)                | ePoster                                                       |